BRPI0413290A - composto para a vacinação de um animal, molécula de ácido nucleico, vetor de expressão, célula hospedeira, vacina, composição farmacêutica, métodos para imunizar um animal contra uma doença, e para combater uma doença em um animal, doença em animal, uso de um composto e um ácido nucleico, e para determinar se a um animal foi administrado com um composto, kit de partes, e, método para vacinar um animal - Google Patents

composto para a vacinação de um animal, molécula de ácido nucleico, vetor de expressão, célula hospedeira, vacina, composição farmacêutica, métodos para imunizar um animal contra uma doença, e para combater uma doença em um animal, doença em animal, uso de um composto e um ácido nucleico, e para determinar se a um animal foi administrado com um composto, kit de partes, e, método para vacinar um animal

Info

Publication number
BRPI0413290A
BRPI0413290A BRPI0413290-4A BRPI0413290A BRPI0413290A BR PI0413290 A BRPI0413290 A BR PI0413290A BR PI0413290 A BRPI0413290 A BR PI0413290A BR PI0413290 A BRPI0413290 A BR PI0413290A
Authority
BR
Brazil
Prior art keywords
animal
compound
disease
nucleic acid
vaccination
Prior art date
Application number
BRPI0413290-4A
Other languages
English (en)
Inventor
Dirk Werling
Original Assignee
Royal Veterinary College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Veterinary College filed Critical Royal Veterinary College
Publication of BRPI0413290A publication Critical patent/BRPI0413290A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

"COMPOSTO PARA A VACINAçãO DE UM ANIMAL, MOLéCULA DE áCIDO NUCLEICO, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, VACINA, COMPOSIçãO FARMACêUTICA, MéTODOS PARA IMUNIZAR UM ANIMAL CONTRA UMA DOENçA, E PARA COMBATER UMA DOENçA EM UM ANIMAL, USO DE UM COMPOSTO, MéTODOS PARA FABRICAR UM COMPOSTO E UM áCIDO NUCLEICO, E PARA DETERMINAR SE A UM ANIMAL FOI ADMINISTRADO COM UM COMPOSTO, KIT DE PARTES, E, MéTODO PRA VACINAR UM ANIMAL". Um composto para a vacinação de um animal que compreende (i) uma porção que seletivamente se liga a uma célula dendrítica no animal mas que não ocorre naturalmente no animal e (ii) um antígeno. Tipicamente, a porção que seletivamente se liga como dito se liga a DC-SIGN. A porção pode ser HIV-1 gp 120. O composto da invenção pode ser usado para vacinar animais e, a seguir da vacinação, eles podem ser distinguidos dos animais naturalmente infectados.
BRPI0413290-4A 2003-08-05 2004-08-05 composto para a vacinação de um animal, molécula de ácido nucleico, vetor de expressão, célula hospedeira, vacina, composição farmacêutica, métodos para imunizar um animal contra uma doença, e para combater uma doença em um animal, doença em animal, uso de um composto e um ácido nucleico, e para determinar se a um animal foi administrado com um composto, kit de partes, e, método para vacinar um animal BRPI0413290A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318247.4A GB0318247D0 (en) 2003-08-05 2003-08-05 Antigen delivery system
PCT/GB2004/003386 WO2005014040A2 (en) 2003-08-05 2004-08-05 Antigen delivery system

Publications (1)

Publication Number Publication Date
BRPI0413290A true BRPI0413290A (pt) 2006-10-10

Family

ID=27839615

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413290-4A BRPI0413290A (pt) 2003-08-05 2004-08-05 composto para a vacinação de um animal, molécula de ácido nucleico, vetor de expressão, célula hospedeira, vacina, composição farmacêutica, métodos para imunizar um animal contra uma doença, e para combater uma doença em um animal, doença em animal, uso de um composto e um ácido nucleico, e para determinar se a um animal foi administrado com um composto, kit de partes, e, método para vacinar um animal

Country Status (18)

Country Link
US (1) US20070142312A1 (pt)
EP (1) EP1667715B1 (pt)
JP (1) JP2007501009A (pt)
KR (1) KR20060125675A (pt)
CN (1) CN1867356A (pt)
AT (1) ATE443525T1 (pt)
AU (1) AU2004262980B2 (pt)
BR (1) BRPI0413290A (pt)
CA (1) CA2533550A1 (pt)
DE (1) DE602004023311D1 (pt)
ES (1) ES2356344T3 (pt)
GB (1) GB0318247D0 (pt)
MX (1) MXPA06001416A (pt)
NO (1) NO20060395L (pt)
NZ (1) NZ544965A (pt)
RU (1) RU2006106738A (pt)
WO (1) WO2005014040A2 (pt)
ZA (1) ZA200601024B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100087344A (ko) 2007-10-29 2010-08-04 버지니아 테크 인터렉추얼 프라퍼티스, 인크. 돼지 ＤＣ-ＳＩＧＮ, ＩＣＡＭ－３ 및 ＬＳＥＣｔｉｎ 및 이의 용도
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
US10193304B2 (en) * 2016-07-01 2019-01-29 Intel Corporation Failsafe pulsed laser driver

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
EP0808366A1 (en) * 1995-01-31 1997-11-26 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6391567B1 (en) * 2000-03-02 2002-05-21 New York University Identifying compounds inhibiting DC-sign facilitation of HIV into cells
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
WO2003084467A2 (en) * 2002-04-01 2003-10-16 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2004092195A2 (en) * 2003-04-09 2004-10-28 Administrators Of The Tulane Educational Fund Dendritic cell binding proteins and uses thereof

Also Published As

Publication number Publication date
CN1867356A (zh) 2006-11-22
CA2533550A1 (en) 2005-02-17
EP1667715B1 (en) 2009-09-23
EP1667715A2 (en) 2006-06-14
WO2005014040A3 (en) 2005-04-28
GB0318247D0 (en) 2003-09-10
ES2356344T3 (es) 2011-04-07
US20070142312A1 (en) 2007-06-21
JP2007501009A (ja) 2007-01-25
AU2004262980A1 (en) 2005-02-17
NO20060395L (no) 2006-03-06
ZA200601024B (en) 2008-07-30
KR20060125675A (ko) 2006-12-06
DE602004023311D1 (de) 2009-11-05
NZ544965A (en) 2009-02-28
MXPA06001416A (es) 2006-05-15
RU2006106738A (ru) 2006-07-27
AU2004262980B2 (en) 2010-04-22
ATE443525T1 (de) 2009-10-15
WO2005014040A2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
Li et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
ES2875589T3 (es) Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
US20260090989A1 (en) LIPID NANOPARTICLE mRNA VACCINES
WO2021159985A1 (en) Vaccine agent for treating or preventing coronavirus disease
BRPI0414381A (pt) composição de adjuvante, composição ou composições imunogênica(s), composição de vacina, processo para a fabricação de uma composição imunogênica, composição ou composições farmacêutica(s), kit, métodos para tratar um paciente que sofre de, ou que é suscetìvel a, um tumor, para incrementar uma resposta imune de um mamìfero a um antìgeno e para suscitar uma resposta imune em m mamìfero contra um estado de doença, usos de uma imidazoquinolina ou derivado da mesma e gm-csf e dos componentes
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CN117858701A (zh) 自组装病毒刺突-eabr纳米颗粒
YU102203A (sh) Vakcinacija sa jednokratnom dozom mycoplasma hyopneumoniae
Araújo et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2
CY1113693T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CN107949636B (zh) 活减毒病毒以及生产和使用方法
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
CY1115926T1 (el) Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης
JP2017533886A5 (pt)
Burgess et al. A recombinant subunit vaccine for the control of ovine psoroptic mange (sheep scab)
CN116917266A (zh) 可离子化脂质及其制造和使用方法
Chen et al. Immune response and protective efficacy of mannosylated polyethylenimine (PEI) as an antigen delivery vector, administered with a Streptococcus agalactiae DNA vaccine in Nile tilapia (Oreochromis niloticus)
MA29244B1 (fr) Compositions permettant d'immuniser contre une mycobacterie
US20190100756A1 (en) CpG-OLIGODEOXYNUCLEOTIDE, IMMUNOGENIC COMPOSITION INCLUDING THE SAME, AND METHOD OF INDUCING IMMUNE RESPONSE BY THE SAME
CN115996751A (zh) 与离子液体佐剂有关的方法和组合物
US20250049904A1 (en) Immunostimulatory compositions
WO2024076715A1 (en) Methods and compositions relating to improved ionic liquid adjuvants
NO20060395L (no) Antigenholdig dyrevaksine

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]